Global Peptide Cancer Vaccine Market Insights, Forecast to 2026

Global Peptide Cancer Vaccine Market Insights, Forecast to 2026

Table of Contents
1 Study Coverage
1.1 Peptide Cancer Vaccine Product Introduction
1.2 Market Segments
1.3 Key Peptide Cancer Vaccine Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Peptide Cancer Vaccine Market Size Growth Rate by Type
1.4.2 Type I
1.4.3 Type II
1.5 Market by Application
1.5.1 Global Peptide Cancer Vaccine Market Size Growth Rate by Application
1.5.2 Breast Cancer
1.5.3 Lung Cancer
1.5.4 Melanoma
1.5.5 Prostate Cancer
1.5.6 Others
1.6 Coronavirus Disease 2019 (Covid-19): Peptide Cancer Vaccine Industry Impact
1.6.1 How the Covid-19 is Affecting the Peptide Cancer Vaccine Industry
1.6.1.1 Peptide Cancer Vaccine Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Peptide Cancer Vaccine Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Peptide Cancer Vaccine Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 Executive Summary
2.1 Global Peptide Cancer Vaccine Market Size Estimates and Forecasts
2.1.1 Global Peptide Cancer Vaccine Revenue 2015-2026
2.1.2 Global Peptide Cancer Vaccine Sales 2015-2026
2.2 Peptide Cancer Vaccine Market Size by Region: 2020 Versus 2026
2.2.1 Global Peptide Cancer Vaccine Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Peptide Cancer Vaccine Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Peptide Cancer Vaccine Competitor Landscape by Players
3.1 Peptide Cancer Vaccine Sales by Manufacturers
3.1.1 Peptide Cancer Vaccine Sales by Manufacturers (2015-2020)
3.1.2 Peptide Cancer Vaccine Sales Market Share by Manufacturers (2015-2020)
3.2 Peptide Cancer Vaccine Revenue by Manufacturers
3.2.1 Peptide Cancer Vaccine Revenue by Manufacturers (2015-2020)
3.2.2 Peptide Cancer Vaccine Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Peptide Cancer Vaccine Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Peptide Cancer Vaccine Revenue in 2019
3.2.5 Global Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Peptide Cancer Vaccine Price by Manufacturers
3.4 Peptide Cancer Vaccine Manufacturing Base Distribution, Product Types
3.4.1 Peptide Cancer Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Peptide Cancer Vaccine Product Type
3.4.3 Date of International Manufacturers Enter into Peptide Cancer Vaccine Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Peptide Cancer Vaccine Market Size by Type (2015-2020)
4.1.1 Global Peptide Cancer Vaccine Sales by Type (2015-2020)
4.1.2 Global Peptide Cancer Vaccine Revenue by Type (2015-2020)
4.1.3 Peptide Cancer Vaccine Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Peptide Cancer Vaccine Market Size Forecast by Type (2021-2026)
4.2.1 Global Peptide Cancer Vaccine Sales Forecast by Type (2021-2026)
4.2.2 Global Peptide Cancer Vaccine Revenue Forecast by Type (2021-2026)
4.2.3 Peptide Cancer Vaccine Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Peptide Cancer Vaccine Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Breakdown Data by Application (2015-2026)
5.1 Global Peptide Cancer Vaccine Market Size by Application (2015-2020)
5.1.1 Global Peptide Cancer Vaccine Sales by Application (2015-2020)
5.1.2 Global Peptide Cancer Vaccine Revenue by Application (2015-2020)
5.1.3 Peptide Cancer Vaccine Price by Application (2015-2020)
5.2 Peptide Cancer Vaccine Market Size Forecast by Application (2021-2026)
5.2.1 Global Peptide Cancer Vaccine Sales Forecast by Application (2021-2026)
5.2.2 Global Peptide Cancer Vaccine Revenue Forecast by Application (2021-2026)
5.2.3 Global Peptide Cancer Vaccine Price Forecast by Application (2021-2026)
6 North America
6.1 North America Peptide Cancer Vaccine by Country
6.1.1 North America Peptide Cancer Vaccine Sales by Country
6.1.2 North America Peptide Cancer Vaccine Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Peptide Cancer Vaccine Market Facts & Figures by Type
6.3 North America Peptide Cancer Vaccine Market Facts & Figures by Application
7 Europe
7.1 Europe Peptide Cancer Vaccine by Country
7.1.1 Europe Peptide Cancer Vaccine Sales by Country
7.1.2 Europe Peptide Cancer Vaccine Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Peptide Cancer Vaccine Market Facts & Figures by Type
7.3 Europe Peptide Cancer Vaccine Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Peptide Cancer Vaccine by Region
8.1.1 Asia Pacific Peptide Cancer Vaccine Sales by Region
8.1.2 Asia Pacific Peptide Cancer Vaccine Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Peptide Cancer Vaccine Market Facts & Figures by Type
8.3 Asia Pacific Peptide Cancer Vaccine Market Facts & Figures by Application
9 Latin America
9.1 Latin America Peptide Cancer Vaccine by Country
9.1.1 Latin America Peptide Cancer Vaccine Sales by Country
9.1.2 Latin America Peptide Cancer Vaccine Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Peptide Cancer Vaccine Market Facts & Figures by Type
9.3 Central & South America Peptide Cancer Vaccine Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Peptide Cancer Vaccine by Country
10.1.1 Middle East and Africa Peptide Cancer Vaccine Sales by Country
10.1.2 Middle East and Africa Peptide Cancer Vaccine Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 UAE
10.2 Middle East and Africa Peptide Cancer Vaccine Market Facts & Figures by Type
10.3 Middle East and Africa Peptide Cancer Vaccine Market Facts & Figures by Application
11 Company Profiles
11.1 TapImmune
11.1.1 TapImmune Corporation Information
11.1.2 TapImmune Description, Business Overview and Total Revenue
11.1.3 TapImmune Sales, Revenue and Gross Margin (2015-2020)
11.1.4 TapImmune Peptide Cancer Vaccine Products Offered
11.1.5 TapImmune Recent Development
11.2 BrightPath Biotherapeutics
11.2.1 BrightPath Biotherapeutics Corporation Information
11.2.2 BrightPath Biotherapeutics Description, Business Overview and Total Revenue
11.2.3 BrightPath Biotherapeutics Sales, Revenue and Gross Margin (2015-2020)
11.2.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Products Offered
11.2.5 BrightPath Biotherapeutics Recent Development
11.3 Ultimovacs
11.3.1 Ultimovacs Corporation Information
11.3.2 Ultimovacs Description, Business Overview and Total Revenue
11.3.3 Ultimovacs Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Ultimovacs Peptide Cancer Vaccine Products Offered
11.3.5 Ultimovacs Recent Development
11.4 Sellas
11.4.1 Sellas Corporation Information
11.4.2 Sellas Description, Business Overview and Total Revenue
11.4.3 Sellas Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Sellas Peptide Cancer Vaccine Products Offered
11.4.5 Sellas Recent Development
11.5 Boston Biomedical
11.5.1 Boston Biomedical Corporation Information
11.5.2 Boston Biomedical Description, Business Overview and Total Revenue
11.5.3 Boston Biomedical Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Boston Biomedical Peptide Cancer Vaccine Products Offered
11.5.5 Boston Biomedical Recent Development
11.6 Imugene
11.6.1 Imugene Corporation Information
11.6.2 Imugene Description, Business Overview and Total Revenue
11.6.3 Imugene Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Imugene Peptide Cancer Vaccine Products Offered
11.6.5 Imugene Recent Development
11.7 VAXON Biotech
11.7.1 VAXON Biotech Corporation Information
11.7.2 VAXON Biotech Description, Business Overview and Total Revenue
11.7.3 VAXON Biotech Sales, Revenue and Gross Margin (2015-2020)
11.7.4 VAXON Biotech Peptide Cancer Vaccine Products Offered
11.7.5 VAXON Biotech Recent Development
11.8 Generex Biotechnology
11.8.1 Generex Biotechnology Corporation Information
11.8.2 Generex Biotechnology Description, Business Overview and Total Revenue
11.8.3 Generex Biotechnology Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Generex Biotechnology Peptide Cancer Vaccine Products Offered
11.8.5 Generex Biotechnology Recent Development
11.9 ISA Pharmaceuticals
11.9.1 ISA Pharmaceuticals Corporation Information
11.9.2 ISA Pharmaceuticals Description, Business Overview and Total Revenue
11.9.3 ISA Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.9.4 ISA Pharmaceuticals Peptide Cancer Vaccine Products Offered
11.9.5 ISA Pharmaceuticals Recent Development
11.10 OncoTherapy Science
11.10.1 OncoTherapy Science Corporation Information
11.10.2 OncoTherapy Science Description, Business Overview and Total Revenue
11.10.3 OncoTherapy Science Sales, Revenue and Gross Margin (2015-2020)
11.10.4 OncoTherapy Science Peptide Cancer Vaccine Products Offered
11.10.5 OncoTherapy Science Recent Development
11.1 TapImmune
11.1.1 TapImmune Corporation Information
11.1.2 TapImmune Description, Business Overview and Total Revenue
11.1.3 TapImmune Sales, Revenue and Gross Margin (2015-2020)
11.1.4 TapImmune Peptide Cancer Vaccine Products Offered
11.1.5 TapImmune Recent Development
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Peptide Cancer Vaccine Market Estimates and Projections by Region
12.1.1 Global Peptide Cancer Vaccine Sales Forecast by Regions 2021-2026
12.1.2 Global Peptide Cancer Vaccine Revenue Forecast by Regions 2021-2026
12.2 North America Peptide Cancer Vaccine Market Size Forecast (2021-2026)
12.2.1 North America: Peptide Cancer Vaccine Sales Forecast (2021-2026)
12.2.2 North America: Peptide Cancer Vaccine Revenue Forecast (2021-2026)
12.2.3 North America: Peptide Cancer Vaccine Market Size Forecast by Country (2021-2026)
12.3 Europe Peptide Cancer Vaccine Market Size Forecast (2021-2026)
12.3.1 Europe: Peptide Cancer Vaccine Sales Forecast (2021-2026)
12.3.2 Europe: Peptide Cancer Vaccine Revenue Forecast (2021-2026)
12.3.3 Europe: Peptide Cancer Vaccine Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Peptide Cancer Vaccine Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Peptide Cancer Vaccine Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Peptide Cancer Vaccine Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Peptide Cancer Vaccine Market Size Forecast by Region (2021-2026)
12.5 Latin America Peptide Cancer Vaccine Market Size Forecast (2021-2026)
12.5.1 Latin America: Peptide Cancer Vaccine Sales Forecast (2021-2026)
12.5.2 Latin America: Peptide Cancer Vaccine Revenue Forecast (2021-2026)
12.5.3 Latin America: Peptide Cancer Vaccine Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Peptide Cancer Vaccine Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Peptide Cancer Vaccine Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Peptide Cancer Vaccine Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Peptide Cancer Vaccine Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Peptide Cancer Vaccine Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Peptide Cancer Vaccine Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
List of Tables
Table 1. Peptide Cancer Vaccine Market Segments
Table 2. Ranking of Global Top Peptide Cancer Vaccine Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Peptide Cancer Vaccine Market Size Growth Rate by Type 2020-2026 (K Doses) & (US$ Million)
Table 4. Major Manufacturers of Type I
Table 5. Major Manufacturers of Type II
Table 6. COVID-19 Impact Global Market: (Four Peptide Cancer Vaccine Market Size Forecast Scenarios)
Table 7. Opportunities and Trends for Peptide Cancer Vaccine Players in the COVID-19 Landscape
Table 8. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 9. Key Regions/Countries Measures against Covid-19 Impact
Table 10. Proposal for Peptide Cancer Vaccine Players to Combat Covid-19 Impact
Table 11. Global Peptide Cancer Vaccine Market Size Growth Rate by Application 2020-2026 (K Doses)
Table 12. Global Peptide Cancer Vaccine Market Size by Region (K Doses) & (US$ Million): 2020 VS 2026
Table 13. Global Peptide Cancer Vaccine Sales by Regions 2015-2020 (K Doses)
Table 14. Global Peptide Cancer Vaccine Sales Market Share by Regions (2015-2020)
Table 15. Global Peptide Cancer Vaccine Revenue by Regions 2015-2020 (US$ Million)
Table 16. Global Peptide Cancer Vaccine Sales by Manufacturers (2015-2020) (K Doses)
Table 17. Global Peptide Cancer Vaccine Sales Share by Manufacturers (2015-2020)
Table 18. Global Peptide Cancer Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 19. Global Peptide Cancer Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptide Cancer Vaccine as of 2019)
Table 20. Peptide Cancer Vaccine Revenue by Manufacturers (2015-2020) (US$ Million)
Table 21. Peptide Cancer Vaccine Revenue Share by Manufacturers (2015-2020)
Table 22. Key Manufacturers Peptide Cancer Vaccine Price (2015-2020) (USD/Dose)
Table 23. Peptide Cancer Vaccine Manufacturers Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Peptide Cancer Vaccine Product Type
Table 25. Date of International Manufacturers Enter into Peptide Cancer Vaccine Market
Table 26. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 27. Global Peptide Cancer Vaccine Sales by Type (2015-2020) (K Doses)
Table 28. Global Peptide Cancer Vaccine Sales Share by Type (2015-2020)
Table 29. Global Peptide Cancer Vaccine Revenue by Type (2015-2020) (US$ Million)
Table 30. Global Peptide Cancer Vaccine Revenue Share by Type (2015-2020)
Table 31. Peptide Cancer Vaccine Average Selling Price (ASP) by Type 2015-2020 (USD/Dose)
Table 32. Global Peptide Cancer Vaccine Sales by Application (2015-2020) (K Doses)
Table 33. Global Peptide Cancer Vaccine Sales Share by Application (2015-2020)
Table 34. North America Peptide Cancer Vaccine Sales by Country (2015-2020) (K Doses)
Table 35. North America Peptide Cancer Vaccine Sales Market Share by Country (2015-2020)
Table 36. North America Peptide Cancer Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 37. North America Peptide Cancer Vaccine Revenue Market Share by Country (2015-2020)
Table 38. North America Peptide Cancer Vaccine Sales by Type (2015-2020) (K Doses)
Table 39. North America Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
Table 40. North America Peptide Cancer Vaccine Sales by Application (2015-2020) (K Doses)
Table 41. North America Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)
Table 42. Europe Peptide Cancer Vaccine Sales by Country (2015-2020) (K Doses)
Table 43. Europe Peptide Cancer Vaccine Sales Market Share by Country (2015-2020)
Table 44. Europe Peptide Cancer Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 45. Europe Peptide Cancer Vaccine Revenue Market Share by Country (2015-2020)
Table 46. Europe Peptide Cancer Vaccine Sales by Type (2015-2020) (K Doses)
Table 47. Europe Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
Table 48. Europe Peptide Cancer Vaccine Sales by Application (2015-2020) (K Doses)
Table 49. Europe Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)
Table 50. Asia Pacific Peptide Cancer Vaccine Sales by Region (2015-2020) (K Doses)
Table 51. Asia Pacific Peptide Cancer Vaccine Sales Market Share by Region (2015-2020)
Table 52. Asia Pacific Peptide Cancer Vaccine Revenue by Region (2015-2020) (US$ Million)
Table 53. Asia Pacific Peptide Cancer Vaccine Revenue Market Share by Region (2015-2020)
Table 54. Asia Pacific Peptide Cancer Vaccine Sales by Type (2015-2020) (K Doses)
Table 55. Asia Pacific Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
Table 56. Asia Pacific Peptide Cancer Vaccine Sales by Application (2015-2020) (K Doses)
Table 57. Asia Pacific Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)
Table 58. Latin America Peptide Cancer Vaccine Sales by Country (2015-2020) (K Doses)
Table 59. Latin America Peptide Cancer Vaccine Sales Market Share by Country (2015-2020)
Table 60. Latin Americaa Peptide Cancer Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 61. Latin America Peptide Cancer Vaccine Revenue Market Share by Country (2015-2020)
Table 62. Latin America Peptide Cancer Vaccine Sales by Type (2015-2020) (K Doses)
Table 63. Latin America Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
Table 64. Latin America Peptide Cancer Vaccine Sales by Application (2015-2020) (K Doses)
Table 65. Latin America Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)
Table 66. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2015-2020) (K Doses)
Table 67. Middle East and Africa Peptide Cancer Vaccine Sales Market Share by Country (2015-2020)
Table 68. Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 69. Middle East and Africa Peptide Cancer Vaccine Revenue Market Share by Country (2015-2020)
Table 70. Middle East and Africa Peptide Cancer Vaccine Sales by Type (2015-2020) (K Doses)
Table 71. Middle East and Africa Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
Table 72. Middle East and Africa Peptide Cancer Vaccine Sales by Application (2015-2020) (K Doses)
Table 73. Middle East and Africa Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)
Table 74. TapImmune Corporation Information
Table 75. TapImmune Description and Major Businesses
Table 76. TapImmune Peptide Cancer Vaccine Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 77. TapImmune Product
Table 78. TapImmune Recent Development
Table 79. BrightPath Biotherapeutics Corporation Information
Table 80. BrightPath Biotherapeutics Description and Major Businesses
Table 81. BrightPath Biotherapeutics Peptide Cancer Vaccine Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 82. BrightPath Biotherapeutics Product
Table 83. BrightPath Biotherapeutics Recent Development
Table 84. Ultimovacs Corporation Information
Table 85. Ultimovacs Description and Major Businesses
Table 86. Ultimovacs Peptide Cancer Vaccine Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 87. Ultimovacs Product
Table 88. Ultimovacs Recent Development
Table 89. Sellas Corporation Information
Table 90. Sellas Description and Major Businesses
Table 91. Sellas Peptide Cancer Vaccine Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 92. Sellas Product
Table 93. Sellas Recent Development
Table 94. Boston Biomedical Corporation Information
Table 95. Boston Biomedical Description and Major Businesses
Table 96. Boston Biomedical Peptide Cancer Vaccine Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 97. Boston Biomedical Product
Table 98. Boston Biomedical Recent Development
Table 99. Imugene Corporation Information
Table 100. Imugene Description and Major Businesses
Table 101. Imugene Peptide Cancer Vaccine Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 102. Imugene Product
Table 103. Imugene Recent Development
Table 104. VAXON Biotech Corporation Information
Table 105. VAXON Biotech Description and Major Businesses
Table 106. VAXON Biotech Peptide Cancer Vaccine Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 107. VAXON Biotech Product
Table 108. VAXON Biotech Recent Development
Table 109. Generex Biotechnology Corporation Information
Table 110. Generex Biotechnology Description and Major Businesses
Table 111. Generex Biotechnology Peptide Cancer Vaccine Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 112. Generex Biotechnology Product
Table 113. Generex Biotechnology Recent Development
Table 114. ISA Pharmaceuticals Corporation Information
Table 115. ISA Pharmaceuticals Description and Major Businesses
Table 116. ISA Pharmaceuticals Peptide Cancer Vaccine Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 117. ISA Pharmaceuticals Product
Table 118. ISA Pharmaceuticals Recent Development
Table 119. OncoTherapy Science Corporation Information
Table 120. OncoTherapy Science Description and Major Businesses
Table 121. OncoTherapy Science Peptide Cancer Vaccine Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 122. OncoTherapy Science Product
Table 123. OncoTherapy Science Recent Development
Table 124. Immatics Corporation Information
Table 125. Immatics Description and Major Businesses
Table 126. Immatics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2015-2020)
Table 127. Immatics Product
Table 128. Immatics Recent Development
Table 129. Global Peptide Cancer Vaccine Sales Forecast by Regions (2021-2026) (K Doses)
Table 130. Global Peptide Cancer Vaccine Sales Market Share Forecast by Regions (2021-2026)
Table 131. Global Peptide Cancer Vaccine Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 132. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Regions (2021-2026)
Table 133. North America: Peptide Cancer Vaccine Sales Forecast by Country (2021-2026) (K Doses)
Table 134. North America: Peptide Cancer Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 135. Europe: Peptide Cancer Vaccine Sales Forecast by Country (2021-2026) (K Doses)
Table 136. Europe: Peptide Cancer Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 137. Asia Pacific: Peptide Cancer Vaccine Sales Forecast by Region (2021-2026) (K Doses)
Table 138. Asia Pacific: Peptide Cancer Vaccine Revenue Forecast by Region (2021-2026) (US$ Million)
Table 139. Latin America: Peptide Cancer Vaccine Sales Forecast by Country (2021-2026) (K Doses)
Table 140. Latin America: Peptide Cancer Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 141. Middle East and Africa: Peptide Cancer Vaccine Sales Forecast by Country (2021-2026) (K Doses)
Table 142. Middle East and Africa: Peptide Cancer Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 143. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 144. Key Challenges
Table 145. Market Risks
Table 146. Main Points Interviewed from Key Peptide Cancer Vaccine Players
Table 147. Peptide Cancer Vaccine Customers List
Table 148. Peptide Cancer Vaccine Distributors List
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
List of Figures
Figure 1. Peptide Cancer Vaccine Product Picture
Figure 2. Global Peptide Cancer Vaccine Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Peptide Cancer Vaccine Sales Market Share by Application in 2020 & 2026
Figure 6. Breast Cancer
Figure 7. Lung Cancer
Figure 8. Melanoma
Figure 9. Prostate Cancer
Figure 10. Others
Figure 11. Peptide Cancer Vaccine Report Years Considered
Figure 12. Global Peptide Cancer Vaccine Market Size 2015-2026 (US$ Million)
Figure 13. Global Peptide Cancer Vaccine Sales 2015-2026 (K Doses)
Figure 14. Global Peptide Cancer Vaccine Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Peptide Cancer Vaccine Sales Market Share by Region (2015-2020)
Figure 16. Global Peptide Cancer Vaccine Sales Market Share by Region in 2019
Figure 17. Global Peptide Cancer Vaccine Revenue Market Share by Region (2015-2020)
Figure 18. Global Peptide Cancer Vaccine Revenue Market Share by Region in 2019
Figure 19. Global Peptide Cancer Vaccine Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Peptide Cancer Vaccine Revenue in 2019
Figure 21. Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
Figure 23. Global Peptide Cancer Vaccine Sales Market Share by Type in 2019
Figure 24. Global Peptide Cancer Vaccine Revenue Market Share by Type (2015-2020)
Figure 25. Global Peptide Cancer Vaccine Revenue Market Share by Type in 2019
Figure 26. Global Peptide Cancer Vaccine Market Share by Price Range (2015-2020)
Figure 27. Global Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)
Figure 28. Global Peptide Cancer Vaccine Sales Market Share by Application in 2019
Figure 29. Global Peptide Cancer Vaccine Revenue Market Share by Application (2015-2020)
Figure 30. Global Peptide Cancer Vaccine Revenue Market Share by Application in 2019
Figure 31. North America Peptide Cancer Vaccine Sales Growth Rate 2015-2020 (K Doses)
Figure 32. North America Peptide Cancer Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Peptide Cancer Vaccine Sales Market Share by Country in 2019
Figure 34. North America Peptide Cancer Vaccine Revenue Market Share by Country in 2019
Figure 35. U.S. Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 36. U.S. Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 38. Canada Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Peptide Cancer Vaccine Market Share by Type in 2019
Figure 40. North America Peptide Cancer Vaccine Market Share by Application in 2019
Figure 41. Europe Peptide Cancer Vaccine Sales Growth Rate 2015-2020 (K Doses)
Figure 42. Europe Peptide Cancer Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Peptide Cancer Vaccine Sales Market Share by Country in 2019
Figure 44. Europe Peptide Cancer Vaccine Revenue Market Share by Country in 2019
Figure 45. Germany Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 46. Germany Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 48. France Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 50. U.K. Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 52. Italy Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 54. Russia Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Peptide Cancer Vaccine Market Share by Type in 2019
Figure 56. Europe Peptide Cancer Vaccine Market Share by Application in 2019
Figure 57. Asia Pacific Peptide Cancer Vaccine Sales Growth Rate 2015-2020 (K Doses)
Figure 58. Asia Pacific Peptide Cancer Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Peptide Cancer Vaccine Sales Market Share by Region in 2019
Figure 60. Asia Pacific Peptide Cancer Vaccine Revenue Market Share by Region in 2019
Figure 61. China Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 62. China Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 64. Japan Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 66. South Korea Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 68. India Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 70. Australia Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 72. Taiwan Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 74. Indonesia Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 76. Thailand Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 78. Malaysia Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 80. Philippines Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 82. Vietnam Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Peptide Cancer Vaccine Market Share by Type in 2019
Figure 84. Asia Pacific Peptide Cancer Vaccine Market Share by Application in 2019
Figure 85. Latin America Peptide Cancer Vaccine Sales Growth Rate 2015-2020 (K Doses)
Figure 86. Latin America Peptide Cancer Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Peptide Cancer Vaccine Sales Market Share by Country in 2019
Figure 88. Latin America Peptide Cancer Vaccine Revenue Market Share by Country in 2019
Figure 89. Mexico Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 90. Mexico Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 92. Brazil Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 94. Argentina Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Peptide Cancer Vaccine Market Share by Type in 2019
Figure 96. Latin America Peptide Cancer Vaccine Market Share by Application in 2019
Figure 97. Middle East and Africa Peptide Cancer Vaccine Sales Growth Rate 2015-2020 (K Doses)
Figure 98. Middle East and Africa Peptide Cancer Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Peptide Cancer Vaccine Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Peptide Cancer Vaccine Revenue Market Share by Country in 2019
Figure 101. Turkey Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 102. Turkey Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 104. Saudi Arabia Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. UAE Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses)
Figure 106. UAE Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Peptide Cancer Vaccine Market Share by Type in 2019
Fi

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global BCG Vaccine Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 96

According to our LPI (LP Information) latest study, the global BCG Vaccine market size was valued at US$ 365.6 million in 2023. With growing demand in downstream market, the BCG Vaccine is forecast to a readjusted size of US$ 542.8 million by 2030 with a CAGR of 5.8% during review period. The research report highlights the growth potential of the global BCG Vaccine market. BCG Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing cost......

Global Peptide Cancer Vaccine Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 115

According to our LPI (LP Information) latest study, the global Peptide Cancer Vaccine market size was valued at US$ 535 million in 2023. With growing demand in downstream market, the Peptide Cancer Vaccine is forecast to a readjusted size of US$ 1978.2 million by 2030 with a CAGR of 20.5% during review period. The research report highlights the growth potential of the global Peptide Cancer Vaccine market. Peptide Cancer Vaccine are expected to show stable growth in the future market. How......

Global Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 101

Market Overview of Global Cancer Vaccine market: According to our latest research, the global Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Cancer Vaccine market was estimated at USD 7198.2 million, and it's anticipated to reach USD 33936.62 million in 2028, with a CAGR of 29.49% during the forecast years. A cancer vaccine is a type of immunotherapy that boost the body's natural defenses by stimulating the immune system to recognize and cur......

Global Lung Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 12-Dec-2023        Price: US 3380 Onwards        Pages: 102

Market Overview of Global Lung Cancer Vaccines market: According to our latest research, the global Lung Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Lung Cancer Vaccines market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Lung Cancer Vaccines,A cancer vaccine for lung cance This report covers a research time span from 2018 to 2028, and ......

Global Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 07-Dec-2023        Price: US 3380 Onwards        Pages: 105

Market Overview of Global Cancer Vaccines market: According to our latest research, the global Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Cancer Vaccines market was estimated at USD 5773.14 million, and it's anticipated to reach USD 15406.41 million in 2028, with a CAGR of 17.77% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Vacci......

Global Dendritic Cell Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 110

Market Overview of Global Dendritic Cell Cancer Vaccine market: According to our latest research, the global Dendritic Cell Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Dendritic Cell Cancer Vaccine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Dendritic cells (DC) are one of the major antigen presenting cells found in lymphoid organs. The main fu......

Global BCG Vaccine Market Research Report 2023, Forecast to 2028

Published: 14-Nov-2023        Price: US 2680 Onwards        Pages: 135

BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......

Global BCG Vaccine Professional Survey Report 2023, Forecast to 2028

Published: 14-Nov-2023        Price: US 3280 Onwards        Pages: 105

BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......

Infectious Vaccine Collaboration and Licensing Deals 2016-2023

Published: 01-Nov-2023        Price: US 3995 Onwards        Pages: 300

Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious vaccine deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of infectious vaccine deals from 2016 to 2023. The report provides a detailed understanding and analysis of how and why companies enter infectious vaccine deals. These deals tend to be multicomponent, starting with......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs